Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus

B Raman, DA Bluemke, TF Lüscher… - European heart …, 2022‏ - academic.oup.com
Emerging as a new epidemic, long COVID or post-acute sequelae of coronavirus disease
2019 (COVID-19), a condition characterized by the persistence of COVID-19 symptoms …

Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta …

L Ortega-Paz, M Galli, D Capodanno… - European Heart …, 2022‏ - academic.oup.com
Background The clinical impact of different prophylactic anticoagulation regimens among
hospitalized patients with coronavirus disease 2019 (COVID-19) remains unclear. We …

Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with …

AC Spyropoulos, M Goldin, D Giannis… - JAMA internal …, 2021‏ - jamanetwork.com
Importance Hospitalized patients with COVID-19 are at risk for venous and arterial
thromboembolism and death. Optimal thromboprophylaxis dosing in high-risk patients is …

Surviving Covid-19 with heparin?

H Ten Cate - New England Journal of Medicine, 2021‏ - Mass Medical Soc
Patients who are admitted to the hospital with coronavirus disease 2019 (Covid-19) are at
high risk for thrombosis, particularly venous thromboembolism (VTE). In a meta-analysis of …

Clinical features of thrombosis and bleeding in COVID-19

MR Thomas, M Scully - Blood, The Journal of the American …, 2022‏ - ashpublications.org
Infection with the SARS-CoV-2 virus, resulting in COVID-19 disease, has presented a
unique scenario associated with high rates of thrombosis. The risk of venous thrombosis is …

[HTML][HTML] Therapeutic versus prophylactic bemiparin in hospitalized patients with nonsevere COVID-19 pneumonia (BEMICOP study): an open-label, multicenter …

M Marcos-Jubilar, F Carmona-Torre… - Thrombosis and …, 2022‏ - thieme-connect.com
Thromboprophylaxis with low molecular weight heparin in hospitalized patients with COVID-
19 is mandatory, unless contraindicated. Given the links between inflammation and …

Anticoagulation in COVID-19 patients–An updated systematic review and meta-analysis

S Reis, M Popp, S Schiesser, MI Metzendorf… - Thrombosis …, 2022‏ - Elsevier
Background Thromboembolic events are common complications of COVID-19. Clinical study
results on safety and efficacy of anticoagulation in COVID-19 are controversial. Material and …

The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials

CS Kow, DS Ramachandram, SS Hasan - Journal of Infection and …, 2022‏ - Elsevier
Objective We aimed to perform a meta-analysis to summarize the overall evidence from
randomized controlled trials related to higher-intensity anticoagulation in hospitalized …

Central nervous system outcomes of COVID-19

MF Doyle - Translational Research, 2022‏ - Elsevier
The worldwide pandemic caused by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has infected an estimated 200 million people with over 4 million deaths …

Therapeutic implications of ongoing alveolar viral replication in COVID-19

D McGonagle, MF Kearney, A O'Regan… - The Lancet …, 2022‏ - thelancet.com
In patients with moderate-to-severe COVID-19 pneumonia, an aberrant post-viral alveolitis
with excessive inflammatory responses and immunothrombosis underpins use of …